
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Management of Intraductal Papillary Mucinous Neoplasm (IPMN)
A Comparative Mind Map of Kyoto 2024 (IAP) vs. ACG 2018 Guidelines</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Management of Intraductal Papillary Mucinous Neoplasm (IPMN)</strong><br><em>A Comparative Mind Map of Kyoto 2024 (IAP) vs. ACG 2018 Guidelines</em></summary>
            <div>
                <ul><li>- This mind map synthesizes and compares two major guidelines for the management of pancreatic cysts, with a focus on IPMN.</li><li>- <b>Kyoto 2024</b>: International evidence-based guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (Ohtsuka et al., Pancreatology).</li><li>- <b>ACG 2018</b>: ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts (Elta et al., The American Journal of Gastroenterology).</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended surveillance interval for a BD-IPMN measuring 25mm according to the Kyoto 2024 guidelines?</li><li>- According to ACG 2018, what is the accuracy of MRI or MRCP in determining if a cyst is benign vs. malignant?</li><li>- The Kyoto 2024 guidelines state that Low-Grade Dysplasia (LGD) at a surgical margin justifies completion pancreatectomy. True or False?</li><li>- What is the 5-year disease-specific survival for Solid-Pseudopapillary Neoplasms (SPNs) according to ACG 2018?</li><li>- The Kyoto 2024 guidelines suggest that a family history of pancreatic cancer primarily increases the risk of what specific type of pancreatic cancer development in IPMN patients?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Guideline Comparison: Scope & Key Differences</strong></summary>
            <div>
                <ul><li>- A high-level overview of the differences between the two guidelines.</li></ul>
                
        <details>
            <summary><strong>Scope of Guideline</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: Focuses <u>exclusively on IPMN</u>, providing in-depth, updated recommendations.</li><li>- <b>ACG 2018</b>: Covers <u>all pancreatic cysts</u> (IPMN, MCN, SCA, pseudocysts), serving as a broader guide for gastroenterologists.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Stratification Framework</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: Uses a two-tier system of <u><b>H</b>igh-<b>R</b>isk <b>S</b>tigmata (HRS)</u> and <u><b>W</b>orrisome <b>F</b>eatures (WF)</u>. Explicitly incorporates EUS findings into this framework.</li><li>- <b>ACG 2018</b>: Uses a single list of <u><b>H</b>igh-<b>R</b>isk <b>C</b>haracteristics</u> that warrant referral to a multidisciplinary group or EUS.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance Strategy</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: Proposes a simplified, size-based surveillance protocol and, crucially, introduces the option to <u><b>stop surveillance</b></u> for small, stable BD-IPMNs after 5 years.</li><li>- <b>ACG 2018</b>: Recommends <u>ongoing surveillance</u> if the patient remains a surgical candidate, with potential to lengthen intervals for stable cysts. Does not recommend stopping.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Key Criteria Thresholds</strong></summary>
            <div>
                <ul><li>- The guidelines differ on specific numerical cutoffs for key features.</li><li>- <b>MPD Diameter</b>: Kyoto 2024 uses <q>≥10mm</q> for HRS, while ACG 2018 uses <q>>5mm</q> as a high-risk feature.</li><li>- <b>Cyst Growth Rate</b>: Kyoto 2024 defines WF as <q>≥2.5mm/year</q>, while ACG 2018 uses <q>>3mm/year</q> as a high-risk feature.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis & Initial Work-up</strong></summary>
            <div>
                <ul><li>- Consensus and differences in the initial diagnostic approach to pancreatic cysts.</li></ul>
                
        <details>
            <summary><strong>Initial Imaging</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: <u>MRI/MRCP</u> is the preferred initial imaging modality.</li><li>- <b>Rationale</b>: Non-invasive, no radiation, and superior accuracy for assessing communication with the main pancreatic duct (MPD), a key feature of BD-IPMN.</li></ul>
                
        <details>
            <summary><strong>Imaging Accuracy</strong></summary>
            <div>
                <ul><li>- <b>ACG 2018</b>: Accuracy of MRI/MRCP for diagnosing cyst type is <q>40-50%</q> and for determining benign vs. malignant is <q>55-76%</q>.</li><li>- <b>Kyoto 2024</b>: Overall accuracy for predicting HGD/IC is <q>73-97%</q>, but for diagnosing specific cyst types is <q>47-78%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of Endoscopic Ultrasound (EUS)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: EUS is a secondary tool for further investigation, not a primary screening modality for all cysts.</li><li>- <b>Kyoto 2024</b>: Explicitly recommends EUS for cases with suspicion of HGD/IC and incorporates its findings (mural nodule size, cytology) into the HRS/WF algorithm.</li><li>- <b>ACG 2018</b>: Recommends EUS for indeterminate cysts or when high-risk features are present.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>EUS-Fine Needle Aspiration (FNA) & Cyst Fluid Analysis</strong></summary>
            <div>
                <ul><li>- <b>Indication</b>: Both guidelines agree EUS-FNA should only be performed when the results are <u>likely to alter management</u>.</li><li>- <b>Kyoto 2024</b>: Notes risk of peritoneal seeding is low (<q>2.3%</q> in surgical cases with HGD/IC) and not statistically different from non-FNA group.</li></ul>
                
        <details>
            <summary><strong>Carcinoembryonic Antigen (CEA)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Useful to differentiate mucinous (IPMN/MCN) from non-mucinous cysts.</li><li>- <b>ACG 2018</b>: A cutoff of <q>192 ng/ml</q> is commonly used. A very low level (<q><5 ng/ml</q>) has >95% specificity for non-mucinous cysts.</li><li>- <b>Kyoto 2024</b>: Notes CEA has no correlation with the grade of dysplasia.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cytology</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Low sensitivity but high specificity for HGD/IC.</li><li>- <b>Kyoto 2024</b>: A 'suspicious' or 'positive' result is considered an <b>HRS</b>, with an absolute risk of HGD/IC of <q>91-100%</q>.</li><li>- <b>ACG 2018</b>: 'High-grade dysplasia or pancreatic cancer' on cytology is a <b>high-risk characteristic</b> warranting referral.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Molecular Markers (Kyoto 2024 Focus)</strong></summary>
            <div>
                <ul><li>- More emphasized in the recent Kyoto 2024 guidelines.</li></ul>
                
        <details>
            <summary><strong>To Differentiate Cyst Type</strong></summary>
            <div>
                <ul><li>- <b>Mucinous Cysts (IPMN/MCN)</b>: Presence of <q>KRAS</q> and/or <q>GNAS</q> mutations.</li><li>- <b>Serous Cystic Neoplasm (SCN)</b>: Presence of <q>VHL</q> mutation.</li><li>- <b>GNAS</b> mutation is highly specific for IPMN.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>To Identify HGD/IC</strong></summary>
            <div>
                <ul><li>- Mutations in <q>TP53, SMAD4, CDKN2A, PIK3CA</q> are useful for identifying HGD/IC.</li><li>- These have low sensitivity (<q>9-39%</q>) but high specificity (<q>92-98%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Stratification & Indications for Surgery</strong></summary>
            <div>
                <ul><li>- A direct comparison of the criteria used by each guideline to determine the need for surgery or intensive evaluation.</li></ul>
                
        <details>
            <summary><strong>Kyoto 2024: HRS & WF Framework</strong></summary>
            <div>
                <ul><li>- A structured, two-tiered approach to risk assessment.</li></ul>
                
        <details>
            <summary><strong><b>High-Risk Stigmata (HRS)</b></strong></summary>
            <div>
                <ul><li>- Presence of any HRS suggests a high likelihood of HGD/IC and is an indication for <u>surgical resection</u>.</li></ul>
                
        <details>
            <summary><strong>Obstructive jaundice</strong></summary>
            <div>
                <ul><li>- In a patient with a cystic lesion in the pancreatic head.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Enhancing mural nodule ≥ 5mm or solid component</strong></summary>
            <div>
                <ul><li>- A strong predictor of HGD/IC.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Main Pancreatic Duct (MPD) ≥ 10mm</strong></summary>
            <div>
                <ul><li>- Indicates significant obstruction or involvement.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Suspicious or positive cytology</strong></summary>
            <div>
                <ul><li>- Confers a very high risk (<q>91-100%</q>) of HGD/IC.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Worrisome Features (WF)</b></strong></summary>
            <div>
                <ul><li>- Presence of any WF is an indication for <u>further investigation</u>, typically with <b>EUS</b>.</li></ul>
                
        <details>
            <summary><strong>List of Worrisome Features</strong></summary>
            <div>
                <ul><li>- Cyst size <q>≥30mm</q></li><li>- Enhancing mural nodule <q><5mm</q></li><li>- Thickened/enhancing cyst walls</li><li>- MPD diameter <q>5mm to <10mm</q></li><li>- Abrupt change in MPD caliber with distal atrophy</li><li>- Lymphadenopathy</li><li>- Cyst growth rate <q>≥2.5mm/year</q></li><li>- Elevated serum CA19-9</li><li>- Acute pancreatitis</li><li>- New onset or exacerbation of diabetes mellitus</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG 2018: High-Risk Characteristics Framework</strong></summary>
            <div>
                <ul><li>- A single list of features that trigger referral to a multidisciplinary group and/or EUS±FNA.</li></ul>
                
        <details>
            <summary><strong>List of High-Risk Characteristics</strong></summary>
            <div>
                <ul><li>- <b>Symptoms</b>: Jaundice, acute pancreatitis secondary to the cyst, elevated serum CA 19-9.</li><li>- <b>Imaging Findings</b>: Mural nodule or solid component, MPD diameter <q>>5mm</q>, abrupt change in MPD caliber, cyst size <q>≥3cm</q>.</li><li>- <b>Cytology</b>: Presence of high-grade dysplasia or pancreatic cancer.</li><li>- <b>During Surveillance</b>: Rapid increase in cyst size (<q>>3mm/year</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Direct Comparison of Key Criteria</strong></summary>
            <div>
                <ul><li>- Highlighting the different thresholds between the guidelines.</li></ul>
                
        <details>
            <summary><strong>MPD Diameter</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: Stratified risk. WF at <q>5-9mm</q>, HRS at <q>≥10mm</q>.</li><li>- <b>ACG 2018</b>: Single threshold. High-risk feature at <q>>5mm</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cyst Growth Rate</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: WF at <q>≥2.5mm/year</q>.</li><li>- <b>ACG 2018</b>: High-risk feature at <q>>3mm/year</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Mural Nodule</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: Stratified by size. WF for enhancing nodule <q><5mm</q>, HRS for <q>≥5mm</q>.</li><li>- <b>ACG 2018</b>: Any mural nodule is a high-risk feature, without a size cutoff.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance of Non-Resected IPMN</strong></summary>
            <div>
                <ul><li>- Protocols for monitoring IPMNs that do not meet criteria for immediate resection.</li></ul>
                
        <details>
            <summary><strong>Kyoto 2024 Surveillance Protocol</strong></summary>
            <div>
                <ul><li>- A simplified protocol based on cyst size.</li></ul>
                
        <details>
            <summary><strong>Cyst <20 mm</strong></summary>
            <div>
                <ul><li>- Initial follow-up at <q>6 months</q>.</li><li>- If stable, surveillance every <q>18 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cyst 20 mm to <30 mm</strong></summary>
            <div>
                <ul><li>- Follow-up at <q>6 months</q>, then again at <q>12 months</q>.</li><li>- If stable, surveillance every <q>12 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cyst ≥30 mm</strong></summary>
            <div>
                <ul><li>- Surveillance every <q>6 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG 2018 Surveillance Protocol</strong></summary>
            <div>
                <ul><li>- A more granular protocol for smaller cysts, with more frequent initial imaging.</li></ul>
                
        <details>
            <summary><strong>Cyst <1 cm</strong></summary>
            <div>
                <ul><li>- MRI every <q>2 years</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cyst 1-2 cm</strong></summary>
            <div>
                <ul><li>- MRI every <q>1 year</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cyst 2-3 cm</strong></summary>
            <div>
                <ul><li>- MRI or EUS every <q>6-12 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cyst >3 cm</strong></summary>
            <div>
                <ul><li>- Refer to multidisciplinary group.</li><li>- Consider alternating MRI and EUS every <q>6 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Stopping Surveillance: A Key Difference</strong></summary>
            <div>
                <ul><li>- A major point of divergence between the two guidelines.</li></ul>
                
        <details>
            <summary><strong>Kyoto 2024 Recommendation</strong></summary>
            <div>
                <ul><li>- For small BD-IPMN (<q><20mm</q>) with no morphological changes and no WF after <q>5 years</q> of surveillance, two options are presented:</li></ul>
                
        <details>
            <summary><strong>Option 1: <b>Stop Surveillance</b></strong></summary>
            <div>
                <ul><li>- Based on the low risk of progression of the IPMN itself.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Option 2: <b>Continue Surveillance</b></strong></summary>
            <div>
                <ul><li>- Rationale: To monitor for the possible development of <u>concomitant PDAC</u>, which remains a risk.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG 2018 Recommendation</strong></summary>
            <div>
                <ul><li>- Surveillance should be <u>discontinued</u> only if a patient is <u>no longer a surgical candidate</u>.</li><li>- Does <u>not</u> recommend stopping after 5 years for stable cysts in fit patients.</li><li>- Suggests assessing the utility of ongoing surveillance in patients <q>>75 years old</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surgical Management & Post-Resection Surveillance</strong></summary>
            <div>
                <ul><li>- Guidance for operative strategy and follow-up after surgery.</li></ul>
                
        <details>
            <summary><strong>Surgical Principles</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Organ-preserving partial pancreatectomy for presumed non-invasive IPMN; radical pancreatectomy with lymphadenectomy for suspected IC.</li><li>- <b>Kyoto 2024</b>: Prophylactic total pancreatectomy is <u>not recommended</u> due to metabolic consequences.</li></ul>
                
        <details>
            <summary><strong>Intraoperative Frozen Section (Kyoto 2024)</strong></summary>
            <div>
                <ul><li>- Critical for guiding the extent of resection.</li></ul>
                
        <details>
            <summary><strong>Margin Status & Action</strong></summary>
            <div>
                <ul><li>- <b>IC or HGD</b> at margin ---> <q>Additional resection recommended</q>.</li><li>- <b>LGD</b> at margin ---> <q>Additional resection is <u>unnecessary</u></q>.</li><li>- <b>Denuded duct</b> at margin ---> Not a negative margin; <q>consider additional resection</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Resection Surveillance</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: All resected IPMNs require postoperative surveillance due to the risk of new or progressive disease in the remnant pancreas.</li></ul>
                
        <details>
            <summary><strong>Kyoto 2024 Post-Resection Protocol</strong></summary>
            <div>
                <ul><li>- Median 5-year risk of clinically significant remnant lesions is <q>10%</q>.</li><li>- Surveillance should be continuous as long as the patient is fit for intervention.</li></ul>
                
        <details>
            <summary><strong>Risk Factors for Recurrence</strong></summary>
            <div>
                <ul><li>- <b>HGD</b> in the initial resected specimen.</li><li>- <b>Family history</b> of pancreatic cancer.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance Interval</strong></summary>
            <div>
                <ul><li>- With risk factors ---> Imaging every <q>6 months</q>.</li><li>- Without risk factors ---> Imaging every <q>12 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG 2018 Post-Resection Protocol</strong></summary>
            <div>
                <ul><li>- Stratifies surveillance by the grade of dysplasia found in the resected IPMN.</li></ul>
                
        <details>
            <summary><strong>Surveillance Interval</strong></summary>
            <div>
                <ul><li>- Resected IPMN with <b>HGD</b> ---> Surveillance every <q>6 months</q>.</li><li>- Resected IPMN with <b>LGD</b> ---> Longer intervals, e.g., every <q>24 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance for other resected cysts (ACG 2018)</strong></summary>
            <div>
                <ul><li>- <b>MCNs</b> without invasive cancer ---> <q><u>No</u> postoperative surveillance required</q>.</li><li>- <b>SCAs, pseudocysts</b> ---> <q><u>No</u> follow-up required</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathology & Special Topics</strong></summary>
            <div>
                <ul><li>- Key pathological concepts and other important clinical considerations.</li></ul>
                
        <details>
            <summary><strong>Pathological Aspects (Kyoto 2024)</strong></summary>
            <div>
                <ul><li>- <b>Grades of Dysplasia</b>: Low-Grade (LGD), High-Grade (HGD), Invasive Carcinoma (IC).</li><li>- <b>HGD</b> is equivalent to 'carcinoma in situ'.</li><li>- <b>Morphological Subtypes</b>: Gastric (most common, best prognosis), Intestinal (associated with colloid carcinoma), Pancreatobiliary (worst prognosis).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Concomitant PDAC</strong></summary>
            <div>
                <ul><li>- Refers to the development of a separate pancreatic ductal adenocarcinoma (PDAC) in apancreas that also harbors an IPMN.</li><li>- This is part of the 'dual carcinogenesis' theory for IPMN patients.</li></ul>
                
        <details>
            <summary><strong>Risk & Incidence</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: The yearly incidence of developing concomitant PDAC is <q>0.4-1.0%</q>.</li><li>- The overall risk is about <q>3 to 5-fold</q> higher than in the age-matched general population.</li><li>- It typically arises in patients with small, stable BD-IPMNs, making surveillance challenging.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Regional Discrepancy</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: Highlights that most studies reporting a high risk of concomitant PDAC originate from <u>Japan</u>.</li><li>- In Western countries, the risk appears to be much lower, closer to that of the general population.</li><li>- This discrepancy may be due to different pathological assessment methods (e.g., entire pancreas sectioning in Japan) and higher awareness.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Family History of Pancreatic Cancer</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: A family history of pancreatic cancer (one or more first-degree relatives) is a significant factor in IPMN management.</li></ul>
                
        <details>
            <summary><strong>Impact on IPMN Progression</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: A family history does <u>not</u> appear to increase the risk of an existing IPMN progressing from LGD to HGD/IC.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Impact on Concomitant PDAC</strong></summary>
            <div>
                <ul><li>- <b>Kyoto 2024</b>: A family history is a strong predictor for the metachronous development of <u>concomitant PDAC</u>.</li><li>- This justifies stricter and more prolonged surveillance, especially after resection.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Multifocal IPMNs</strong></summary>
            <div>
                <ul><li>- Incidence of multifocal BD-IPMNs is reported to be <q>20-40%</q>.</li><li>- <b>Consensus</b>: Multifocality itself does <u>not</u> increase the risk of HGD/IC.</li></ul>
                
        <details>
            <summary><strong>Management Strategy</strong></summary>
            <div>
                <ul><li>- Management decisions should be based on the single lesion with the <u>highest-risk features</u>.</li><li>- If surgery is indicated, the goal is to resect only the high-risk lesion, leaving other low-risk cysts to avoid a prophylactic total pancreatectomy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Therapies (Kyoto 2024 Focus)</strong></summary>
            <div>
                <ul><li>- Non-surgical options for IPMN are generally not standard of care.</li></ul>
                
        <details>
            <summary><strong>Chemotherapy & Radiotherapy</strong></summary>
            <div>
                <ul><li>- The role for unresectable IPMN with IC or in an adjuvant setting is not established.</li><li>- In practice, regimens used for standard PDAC are often applied.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Ablation Therapy (e.g., Ethanol)</strong></summary>
            <div>
                <ul><li>- Efficacy is highly variable, with cyst resolution reported in <q>9% to 72%</q> of cases.</li><li>- Adverse event rate is significant at <q>9-23%</q>, with pancreatitis being the most common.</li><li>- Long-term oncological benefit is unproven.</li><li>- <b>Recommendation</b>: Should only be performed within a <u>clinical trial</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Characteristics of Specific Cyst Types (ACG 2018 Focus)</strong></summary>
            <div>
                <ul><li>- The ACG 2018 guideline provides details on various cyst types beyond IPMN.</li></ul>
                
        <details>
            <summary><strong>Mucinous Cystic Neoplasm (MCN)</strong></summary>
            <div>
                <ul><li>- Occur almost exclusively in <q>women</q> (<q>>95%</q>), typically in the 4th-5th decade.</li><li>- Located in the pancreatic <u>body or tail</u> in <q>95%</q> of cases.</li><li>- Characterized by ovarian-type stroma and no communication with the MPD.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Serous Cystadenoma (SCA)</strong></summary>
            <div>
                <ul><li>- More common in women (<q>~70%</q>), typically in the 6th-7th decade.</li><li>- Have an extremely low risk of malignancy (<q>0.1%</q>).</li><li>- Classic imaging: microcystic or honeycomb appearance, with a central scar in <q><30%</q> of cases.</li><li>- Asymptomatic SCAs do not require surveillance.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Solid-Pseudopapillary Neoplasm (SPN)</strong></summary>
            <div>
                <ul><li>- Rare tumors, predominantly in young women (<q>10:1 ratio</q>), often in their 20s.</li><li>- Aggressive behavior (e.g., vascular invasion, metastasis) is found in <q>~10%</q> pathologically.</li><li>- Prognosis after resection is excellent, with a 5-year disease-specific survival of <q>>98%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
